Zijun Yidan Xu-Monette
Assistant Professor in Pathology
My research efforts have been focused on identifying prognostic and therapeutic biomarkers in B-cell lymphoma. My research interests also include investigation of molecular and immune mechanisms underlying the poor clinical outcomes of lymphoma, the pathogenesis and evolution of drug resistant clones, and development of novel therapies for aggressive B-cell lymphoma.
Current Research Interests
- The p53 pathway in lymphoma
- High-grade B-cell lymphomas with double-hit cytogenetics and the MYC biology
- Immunosuppressive mechanisms in lymphomas and determinants shaping the immune response in the tumor microenvironment
- Genetic and epigenetic profiling
- Therapeutic strategies for the refractory/relapsed lymphoma
- New tools for diagnosis, risk prediction, and therapeutic selection in lymphoma.
Current Appointments & Affiliations
- Assistant Professor in Pathology, Pathology, Clinical Science Departments 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2019
Contact Information
- 905 S Lasalle St, Snyderman Gsrb1, Room 1010, Durham, NC 27710
- 905 S Lasalle St, Snyderman Gsrb1, Room 1010, Durham, NC 27710
-
zijun.xumonette@duke.edu
(919) 660-0702
- Background
-
Education, Training, & Certifications
- Ph.D., Michigan Technological University 2009
-
Previous Appointments & Affiliations
- Assistant Professor in Pathology, Pathology, Clinical Science Departments 2019 - 2020
-
Academic Positions Outside Duke
- Instructor, The University of Texas MD Anderson Cancer Center. 2015 - 2019
- Postdoc fellow, The University of Texas MD Anderson Cancer Center. 2011 - 2015
- Postdoc fellow, University of Wisconsin, Madison. 2010
- Research
-
Selected Grants
- Genetic and Epigenetic Biomarkers for B-cell Lymphoma awarded by National Institutes of Health 2020 - 2024
- Spatially resolved, single cell biomarkers of B cell lymphoma awarded by Cedars Sinai Medical Center 2022 - 2023
-
External Relationships
- Journal: The Lancet Haematology. I received an honorarium of $75 for peer reviewing one paper fit in my research scope; the peer review was invited by the The Lancet Haematology.
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Yu, Tiantian, Qing-Qing Cai, Qiong-Li Zhai, Ling Li, Xiaosheng Fang, Jianyong Li, Ruifang Sun, et al. “Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study.” Leuk Lymphoma 63, no. 13 (December 2022): 3082–91. https://doi.org/10.1080/10428194.2022.2118528.Full Text Link to Item
-
Li, Yong, Zijun Y. Xu-Monette, Jeremy S. Abramson, Aliyah Sohani, Govind Bhagat, Alexandar Tzankov, Carlo Visco, et al. “EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.” Blood Adv, November 18, 2022. https://doi.org/10.1182/bloodadvances.2022008550.Full Text Link to Item
-
Elfrink, Suraya, Martin Ter Beest, Luuk Janssen, Marijke P. Baltissen, Pascal W. T. C. Jansen, Angelique N. Kenyon, Raymond M. Steen, et al. “IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.” Blood Adv 6, no. 7 (April 12, 2022): 2254–66. https://doi.org/10.1182/bloodadvances.2021004366.Full Text Link to Item
-
Xu-Monette, Zijun Y., Li Wei, Xiaosheng Fang, Qingyan Au, Harry Nunns, Máté Nagy, Alexandar Tzankov, et al. “Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.” Clin Cancer Res 28, no. 5 (March 1, 2022): 972–83. https://doi.org/10.1158/1078-0432.CCR-21-2949.Full Text Link to Item
-
Albitar, Maher, Hong Zhang, Andre Goy, Zijun Y. Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, et al. “Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.” Blood Cancer J 12, no. 2 (February 1, 2022): 25. https://doi.org/10.1038/s41408-022-00617-5.Full Text Link to Item
-
Liu, Hui, Zijun Y. Xu-Monette, Guilin Tang, Wei Wang, Young Kim, Ji Yuan, Yu Li, et al. “EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.” Histopathology 80, no. 3 (February 2022): 575–88. https://doi.org/10.1111/his.14585.Full Text Link to Item
-
Youssef, Youssef, Vrajesh Karkhanis, Wing Keung Chan, Frankie Jeney, Alessandro Canella, Xiaoli Zhang, Shelby Sloan, et al. “Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.” Haematologica 106, no. 11 (November 1, 2021): 2927–39. https://doi.org/10.3324/haematol.2020.268235.Full Text Link to Item
-
Tian, Xiao-Peng, Shu-Yun Ma, Ken H. Young, Choon Kiat Ong, Yan-Hui Liu, Zhi-Hua Li, Qiong-Li Zhai, et al. “A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma.” Blood 138, no. 6 (August 12, 2021): 452–63. https://doi.org/10.1182/blood.2020010637.Full Text Link to Item
-
Chen, Pu, Lucas Redd, Yao Schmidt, Prasad Koduru, Franklin Fuda, Crystal Montgomery-Goecker, Kirthi Kumar, et al. “MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.” Leuk Res 106 (July 2021): 106584. https://doi.org/10.1016/j.leukres.2021.106584.Full Text Link to Item
-
Wang, Yingjun, Vasantha Lakshmi Gali, Zijun Y. Xu-Monette, Dahlia Sano, Sheeba K. Thomas, Donna M. Weber, Feng Zhu, et al. “Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.” Neoplasia 23, no. 4 (April 2021): 361–74. https://doi.org/10.1016/j.neo.2021.02.002.Full Text Link to Item
-
Yu, Xinfang, Wei Li, Qipan Deng, Haidan Liu, Xu Wang, Hui Hu, Ya Cao, et al. “MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.” Blood 137, no. 12 (March 2021): 1615–27. https://doi.org/10.1182/blood.2020004918.Full Text
-
Deng, Manman, Zijun Y. Xu-Monette, Lan V. Pham, Xudong Wang, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, et al. “Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.” Mol Cancer Res 19, no. 2 (February 2021): 249–60. https://doi.org/10.1158/1541-7786.MCR-20-0466.Full Text Link to Item
-
Fang, Xiaosheng, Zhongling Sun, Zijun Y. Xu-Monette, and Ken H. Young. “Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions.” The Oncologist 26, no. 1 (January 2021): 4–6. https://doi.org/10.1002/onco.13605.Full Text
-
You, Hua, Zijun Y. Xu-Monette, Li Wei, Harry Nunns, Máté L. Nagy, Govind Bhagat, Xiaosheng Fang, et al. “Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.” Oncoimmunology 10, no. 1 (2021): 1928365. https://doi.org/10.1080/2162402X.2021.1928365.Full Text Link to Item
-
Xu-Monette, Zijun Y., and Ken H. Young. “Therapeutic vaccines for aggressive B-cell lymphoma.” Leuk Lymphoma 61, no. 13 (December 2020): 3038–51. https://doi.org/10.1080/10428194.2020.1805113.Full Text Link to Item
-
Deng, Manman, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, et al. “XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.” J Hematol Oncol 13, no. 1 (November 4, 2020): 148. https://doi.org/10.1186/s13045-020-00982-3.Full Text Link to Item
-
Yu, Li, Menghan Shi, Qingqing Cai, Paolo Strati, Fredrick Hagemeister, Qiongli Zhai, Ling Li, et al. “A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.” Oncologist 25, no. 11 (November 2020): 963–73. https://doi.org/10.1634/theoncologist.2019-0986.Full Text Link to Item
-
Chen, Kai, Qianying Yang, Jie Zha, Manman Deng, Yong Zhou, Guofeng Fu, Silei Bi, et al. “Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia.” Cell Death Dis 11, no. 9 (September 18, 2020): 778. https://doi.org/10.1038/s41419-020-02972-2.Full Text Link to Item
-
Liu, Ming, Xu Wang, Wei Li, Xinfang Yu, Pedro Flores-Villanueva, Zijun Y. Xu-Monette, Ling Li, et al. “Targeting PD-L1 in non-small cell lung cancer using CAR T cells.” Oncogenesis 9, no. 8 (August 13, 2020): 72. https://doi.org/10.1038/s41389-020-00257-z.Full Text Link to Item
-
Xu-Monette, Zijun Y., Hongwei Zhang, Feng Zhu, Alexandar Tzankov, Govind Bhagat, Carlo Visco, Karen Dybkaer, et al. “A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.” Blood Adv 4, no. 14 (July 28, 2020): 3391–3404. https://doi.org/10.1182/bloodadvances.2020001949.Full Text Link to Item
-
Zhou, Hui, Zijun Y. Xu-Monette, Ling Xiao, Paolo Strati, Fredrick B. Hagemeister, Yizi He, Huan Chen, et al. “Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.” Blood Cancer J 10, no. 5 (May 4, 2020): 49. https://doi.org/10.1038/s41408-020-0312-7.Full Text Link to Item
-
Yu, Xinfang, Wei Li, Haidan Liu, Qipan Deng, Xu Wang, Hui Hu, Zijun Y. Xu-Monette, et al. “Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation.” J Hematol Oncol 13, no. 1 (May 1, 2020): 40. https://doi.org/10.1186/s13045-020-00869-3.Full Text Link to Item
-
Keane, Colm, Soi C. Law, Clare Gould, Simone Birch, Muhammed B. Sabdia, Lilia Merida de Long, Gayathri Thillaiyampalam, et al. “LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.” Blood Adv 4, no. 7 (April 14, 2020): 1367–77. https://doi.org/10.1182/bloodadvances.2019001390.Full Text Link to Item
-
Gallardo, Miguel, Prerna Malaney, Marisa J. L. Aitken, Xiaorui Zhang, Todd M. Link, Vrutant Shah, Sanzhar Alybayev, et al. “Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.” Journal of the National Cancer Institute 112, no. 1 (January 2020): 95–106. https://doi.org/10.1093/jnci/djz078.Full Text
-
Deng, Qipan, Hui Hu, Xinfang Yu, Shuanglin Liu, Lei Wang, Weiqun Chen, Chi Zhang, et al. “Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.” Nat Commun 10, no. 1 (November 7, 2019): 5061. https://doi.org/10.1038/s41467-019-13002-x.Full Text Link to Item
-
Xu-Monette, Zijun Y., Jianyong Li, Yi Xia, Beryl Crossley, Robert D. Bremel, Yi Miao, Min Xiao, et al. “Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.” J Immunother Cancer 7, no. 1 (October 22, 2019): 272. https://doi.org/10.1186/s40425-019-0730-x.Full Text Link to Item
-
Wang, Lei, Qipan Deng, Hui Hu, Ming Liu, Zhaojian Gong, Shanshan Zhang, Zijun Y. Xu-Monette, et al. “Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.” Journal of Hematology & Oncology 12, no. 1 (July 2019): 70. https://doi.org/10.1186/s13045-019-0767-9.Full Text
-
Li, Ling, Ruifang Sun, Yi Miao, Thai Tran, Lisa Adams, Nathan Roscoe, Bing Xu, et al. “PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 32, no. 6 (June 2019): 741–54. https://doi.org/10.1038/s41379-018-0193-5.Full Text Open Access Copy
-
Xu-Monette, Ziju Y., Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, et al. “Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.” Cancer Immunology Research 7, no. 4 (April 2019): 644–57. https://doi.org/10.1158/2326-6066.cir-18-0439.Full Text
-
Miao, Yi, L Jeffrey Medeiros, Zijun Y. Xu-Monette, Jianyong Li, and Ken H. Young. “Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.” Frontiers in Oncology 9 (January 2019): 107. https://doi.org/10.3389/fonc.2019.00107.Full Text Open Access Copy
-
Wang, Lei, Munish Kumar, Qipan Deng, Xu Wang, Ming Liu, Zhaojian Gong, Shanshan Zhang, et al. “2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice.” Cancer Lett 440–441 (January 2019): 135–44. https://doi.org/10.1016/j.canlet.2018.10.009.Full Text Link to Item
-
Li, Li, Jun Zhang, Juan Chen, Zijun Y. Xu-Monette, Yi Miao, Min Xiao, Ken H. Young, et al. “B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.” Blood 132, no. 17 (October 2018): 1805–17. https://doi.org/10.1182/blood-2018-03-841015.Full Text
-
Wang, Xiaoxiao, Xin Cao, Ruifang Sun, Charlene Tang, Alexandar Tzankov, Jun Zhang, Ganiraju C. Manyam, et al. “Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.” Neoplasia 20, no. 6 (June 2018): 574–93. https://doi.org/10.1016/j.neo.2018.03.002.Full Text Link to Item
-
Yin, Lihui, Zijun Y. Xu-Monette, Jay Brock, Yong Li, and Ken H. Young. “Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations.” Annals of Translational Medicine 6, no. 11 (June 2018): 236. https://doi.org/10.21037/atm.2018.05.36.Full Text
-
García-Barchino, Maria J., Maria E. Sarasquete, Carlos Panizo, Julie Morscio, Antonio Martinez, Miguel Alcoceba, Vicente Fresquet, et al. “Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.” The Journal of Pathology 245, no. 1 (May 2018): 61–73. https://doi.org/10.1002/path.5060.Full Text
-
Jain, N., H. Zhu, T. Khashab, Q. Ye, B. George, R. Mathur, R. K. Singh, et al. “Targeting nucleolin for better survival in diffuse large B-cell lymphoma.” Leukemia 32, no. 3 (March 2018): 663–74. https://doi.org/10.1038/leu.2017.215.Full Text
-
Yao, Z., L. Deng, Z. Y. Xu-Monette, G. C. Manyam, P. Jain, A. Tzankov, C. Visco, et al. “Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.” Leukemia 32, no. 2 (February 2018): 353–63. https://doi.org/10.1038/leu.2017.222.Full Text
-
Xu-Monette, Zijun Y., Jianfeng Zhou, and Ken H. Young. “PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.” Blood 131, no. 1 (January 2018): 68–83. https://doi.org/10.1182/blood-2017-07-740993.Full Text Open Access Copy
-
Visco, Carlo, Jinfen Wang, Maria Chiara Tisi, Lijuan Deng, Emanuele S. G. D’Amore, Alexandar Tzankov, Santiago Montes-Moreno, et al. “Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.” British Journal of Cancer 117, no. 11 (November 2017): 1685–88. https://doi.org/10.1038/bjc.2017.345.Full Text
-
Li, Xin, Zijun Y. Xu-Monette, Shuhua Yi, Bouthaina S. Dabaja, Ganiraju C. Manyam, Jason Westin, Nathan Fowler, et al. “Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.” The American Journal of Surgical Pathology 41, no. 10 (October 2017): 1309–21. https://doi.org/10.1097/pas.0000000000000923.Full Text
-
Wang, Jinfen, Zijun Y. Xu-Monette, Kausar J. Jabbar, Qi Shen, Ganiraju C. Manyam, Alexandar Tzankov, Carlo Visco, et al. “AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.” The American Journal of Pathology 187, no. 8 (August 2017): 1700–1716. https://doi.org/10.1016/j.ajpath.2017.04.009.Full Text
-
Cai, Qingqing, Meifeng Tu, Zijun Y. Xu-Monette, Ruifang Sun, Ganiraju C. Manyam, Xiaolu Xu, Alexander Tzankov, et al. “NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.” Mod Pathol 30, no. 6 (June 2017): 854–76. https://doi.org/10.1038/modpathol.2017.5.Full Text Link to Item
-
Xia, Y., Z. Y. Xu-Monette, A. Tzankov, X. Li, G. C. Manyam, V. Murty, G. Bhagat, et al. “Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.” Leukemia 31, no. 3 (March 2017): 625–36. https://doi.org/10.1038/leu.2016.243.Full Text Open Access Copy
-
Yu, Li, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, et al. “Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.” Blood 129, no. 12 (March 2017): 1658–68. https://doi.org/10.1182/blood-2016-11-748855.Full Text Open Access Copy
-
Xu-Monette, Zijun Y., Mingzhi Zhang, Jianyong Li, and Ken H. Young. “PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?” Frontiers in Immunology 8 (January 2017): 1597. https://doi.org/10.3389/fimmu.2017.01597.Full Text
-
Xu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand, et al. “Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.” Blood 128, no. 26 (December 29, 2016): 3083–3100. https://doi.org/10.1182/blood-2016-05715094.Full Text Open Access Copy Link to Item
-
Loghavi, Sanam, Sa A. Wang, L Jeffrey Medeiros, Jeffrey L. Jorgensen, Xin Li, Zijun Y. Xu-Monette, Roberto N. Miranda, and Ken H. Young. “Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.” Leukemia & Lymphoma 57, no. 12 (December 2016): 2804–12. https://doi.org/10.3109/10428194.2016.1170827.Full Text
-
Mai, Yun, J Jessica Yu, Boris Bartholdy, Zijun Y. Xu-Monette, Esther E. Knapp, Fei Yuan, Hongshan Chen, et al. “An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.” Blood 128, no. 24 (December 2016): 2797–2807. https://doi.org/10.1182/blood-2016-03-705814.Full Text
-
Pham, Lan V., Jerry L. Bryant, Richard Mendez, Juan Chen, Archito T. Tamayo, Zijun Y. Xu-Monette, Ken H. Young, et al. “Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.” Oncotarget 7, no. 49 (December 2016): 80599–611. https://doi.org/10.18632/oncotarget.12413.Full Text
-
Xu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand, et al. “Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.” Blood 128, no. 26 (December 2016): 3083–3100. https://doi.org/10.1182/blood-2016-05-715094.Full Text
-
Zhang, Mingzhi, Zijun Y. Xu-Monette, Ling Li, Ganiraju C. Manyam, Carlo Visco, Alexandar Tzankov, Jing Wang, et al. “RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.” Aging 8, no. 12 (December 2016): 3321–40. https://doi.org/10.18632/aging.101121.Full Text
-
Xu-Monette, Zijun Y., Qipan Deng, Ganiraju C. Manyam, Alexander Tzankov, Ling Li, Yi Xia, Xiao-Xiao Wang, et al. “Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.” Clin Cancer Res 22, no. 14 (July 15, 2016): 3593–3605. https://doi.org/10.1158/1078-0432.CCR-15-2296.Full Text Link to Item
-
Cao, Xin, L Jeffrey Medeiros, Yi Xia, Xiaoxiao Wang, Sheeba K. Thomas, Sanam Loghavi, Xin Li, et al. “Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.” Leukemia & Lymphoma 57, no. 5 (May 2016): 1104–13. https://doi.org/10.3109/10428194.2015.1096357.Full Text
-
Batlle-López, Ana, Sonia González de Villambrosía, Mazorra Francisco, Sefora Malatxeberria, Anabel Sáez, Carlos Montalban, Lydia Sánchez, et al. “Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.” Oncotarget 7, no. 14 (April 2016): 18036–49. https://doi.org/10.18632/oncotarget.7495.Full Text
-
Kanagal-Shamanna, Rashmi, Zijun Y. Xu-Monette, Roberto N. Miranda, Ahmet Dogan, Dehui Zou, Rajyalakshmi Luthra, Donna M. Weber, et al. “Crystal-storing histiocytosis: a clinicopathological study of 13 cases.” Histopathology 68, no. 4 (March 2016): 482–91. https://doi.org/10.1111/his.12768.Full Text Link to Item
-
Deng, L., Z. Y. Xu-Monette, S. Loghavi, G. C. Manyam, Y. Xia, C. Visco, J. Huh, et al. “Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.” Leukemia 30, no. 2 (February 2016): 361–72. https://doi.org/10.1038/leu.2015.237.Full Text
-
Winde, Charlotte M. de, Sharon Veenbergen, Ken H. Young, Zijun Y. Xu-Monette, Xiao-Xiao Wang, Yi Xia, Kausar J. Jabbar, et al. “Tetraspanin CD37 protects against the development of B cell lymphoma.” J Clin Invest 126, no. 2 (February 2016): 653–66. https://doi.org/10.1172/JCI81041.Full Text Link to Item
-
Xu-Monette, Zijun Y., Shanxiang Zhang, Xin Li, Ganiraju C. Manyam, Xiao-Xiao Wang, Yi Xia, Carlo Visco, et al. “p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.” Aging 8, no. 2 (February 2016): 345–65. https://doi.org/10.18632/aging.100898.Full Text
-
Ye, Qing, Zijun Y. Xu-Monette, Alexandar Tzankov, Lijuan Deng, Xiaoxiao Wang, Ganiraju C. Manyam, Carlo Visco, et al. “Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.” Oncotarget 7, no. 3 (January 2016): 2401–16. https://doi.org/10.18632/oncotarget.6262.Full Text
-
Xu-Monette, Zijun Y., Bouthaina S. Dabaja, Xiaoxiao Wang, Meifeng Tu, Ganiraju C. Manyam, Alexander Tzankov, Yi Xia, et al. “Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 28, no. 12 (December 2015): 1555–73. https://doi.org/10.1038/modpathol.2015.118.Full Text
-
Gordon, Michael W., Fang Yan, Xiaoming Zhong, Pranab Behari Mazumder, Zijun Y. Xu-Monette, Dehui Zou, Ken H. Young, Kenneth S. Ramos, and Yong Li. “Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma.” Molecular Carcinogenesis 54, no. 10 (October 2015): 1060–69. https://doi.org/10.1002/mc.22175.Full Text
-
Liu, Zhiyu, Zijun Y. Xu-Monette, Xin Cao, Ganiraju C. Manyam, Xiaoxiao Wang, Alexandar Tzankov, Yi Xia, et al. “Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.” Mod Pathol 28, no. 10 (October 2015): 1297–1314. https://doi.org/10.1038/modpathol.2015.94.Full Text Link to Item
-
Brauner, S., W. Zhou, C. Backlin, T. M. Green, L. Folkersen, M. Ivanchenko, B. Löfström, et al. “Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.” Journal of Internal Medicine 278, no. 3 (September 2015): 323–32. https://doi.org/10.1111/joim.12375.Full Text
-
Li, Ling, Zijun Y. Xu-Monette, Chi Young Ok, Alexandar Tzankov, Ganiraju C. Manyam, Ruifang Sun, Carlo Visco, et al. “Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.” Oncotarget 6, no. 27 (September 2015): 23157–80. https://doi.org/10.18632/oncotarget.4319.Full Text
-
Ok, Chi Young, Zijun Y. Xu-Monette, Ling Li, Ganiraju C. Manyam, Santiago Montes-Moreno, Alexandar Tzankov, Carlo Visco, et al. “Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 28, no. 9 (September 2015): 1202–13. https://doi.org/10.1038/modpathol.2015.76.Full Text
-
Cao, Xin, Qing Ye, Robert Z. Orlowski, Xiaoxiao Wang, Sanam Loghavi, Meifeng Tu, Sheeba K. Thomas, et al. “Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.” J Hematol Oncol 8 (June 24, 2015): 74. https://doi.org/10.1186/s13045-015-0172-y.Full Text Link to Item
-
Xu-Monette, Zijun Y., Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov, Carlo Visco, Lalitha Nagarajan, et al. “Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.” Oncotarget 6, no. 16 (June 10, 2015): 14720. https://doi.org/10.18632/oncotarget.4464.Full Text Link to Item
-
Ok, Chi Young, Qing Ye, Ling Li, Ganiraju C. Manyam, Lijuan Deng, Rashmi R. Goswami, Xiaoxiao Wang, et al. “Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?” Oncotarget 6, no. 16 (June 2015): 13933–45. https://doi.org/10.18632/oncotarget.4324.Full Text
-
Ma, Xiaodong, Daniel J. Conklin, Fenge Li, Zhongping Dai, Xiang Hua, Yan Li, Zijun Y. Xu-Monette, et al. “The oncogenic microRNA miR-21 promotes regulated necrosis in mice.” Nature Communications 6 (May 2015): 7151. https://doi.org/10.1038/ncomms8151.Full Text
-
Dhadi, Surendar Reddy, Zijun Xu, Rafi Shaik, Kyle Driscoll, and Wusirika Ramakrishna. “Differential regulation of genes by retrotransposons in rice promoters.” Plant Mol Biol 87, no. 6 (April 2015): 603–13. https://doi.org/10.1007/s11103-015-0300-7.Full Text Link to Item
-
Dybkær, Karen, Martin Bøgsted, Steffen Falgreen, Julie S. Bødker, Malene K. Kjeldsen, Alexander Schmitz, Anders E. Bilgrau, et al. “Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 12 (April 2015): 1379–88. https://doi.org/10.1200/jco.2014.57.7080.Full Text
-
Falgreen, Steffen, Karen Dybkær, Ken H. Young, Zijun Y. Xu-Monette, Tarec C. El-Galaly, Maria Bach Laursen, Julie S. Bødker, et al. “Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.” Bmc Cancer 15 (April 2015): 235. https://doi.org/10.1186/s12885-015-1237-6.Full Text
-
Chen, Jiayu, Zijun Y. Xu-Monette, Lijuan Deng, Qi Shen, Ganiraju C. Manyam, Azahara Martinez-Lopez, Li Zhang, et al. “Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.” Oncotarget 6, no. 8 (March 2015): 5597–5614. https://doi.org/10.18632/oncotarget.3343.Full Text
-
Xu-Monette, Zijun Y., Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov, Carol Visco, Lalitha Nagarajan, et al. “Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.” Oncotarget 6, no. 8 (March 2015): 5615–33. https://doi.org/10.18632/oncotarget.3479.Full Text
-
Liu, Ju, C. Zhang, X. L. Wang, P. Ly, V. Belyi, Z. Y. Xu-Monette, K. H. Young, W. Hu, and Z. Feng. “E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.” Cell Death and Differentiation 21, no. 11 (November 2014): 1792–1804. https://doi.org/10.1038/cdd.2014.121.Full Text
-
Ok, Chi Young, Jiayu Chen, Zijun Y. Xu-Monette, Alexandar Tzankov, Ganiraju C. Manyam, Ling Li, Carlo Visco, et al. “Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 20, no. 19 (October 2014): 5113–23. https://doi.org/10.1158/1078-0432.ccr-14-0683.Full Text
-
Yu, Haiyang, Xuetian Yue, Yuhan Zhao, Xiaoyan Li, Lihua Wu, Cen Zhang, Zhen Liu, et al. “LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.” Nature Communications 5 (October 2014): 5218. https://doi.org/10.1038/ncomms6218.Full Text
-
Ok, C. Y., L. Li, Z. Y. Xu-Monette, C. Visco, A. Tzankov, and G. C. Manyam. “Erratum: Prevalence and clinical implications of epstein-barr virus infection inDeNovo diffuse large B-Cell lymphoma in Western Countries (Clin Cancer Res (2014) 20 (2338-2349)).” Clinical Cancer Research 20, no. 18 (September 15, 2014): 4974. https://doi.org/10.1158/1078-0432.CCR-14-1858.Full Text
-
Wang, Shi, L Jeffrey Medeiros, Zijun Y. Xu-Monette, Shanxiang Zhang, Dennis P. O’Malley, Attilio Orazi, Zhuang Zuo, et al. “Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.” Annals of Diagnostic Pathology 18, no. 4 (August 2014): 203–9. https://doi.org/10.1016/j.anndiagpath.2014.03.007.Full Text
-
Tzankov, Alexandar, Zijun Y. Xu-Monette, Marc Gerhard, Carlo Visco, Stephan Dirnhofer, Nora Gisin, Karen Dybkaer, et al. “Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 27, no. 7 (July 2014): 958–71. https://doi.org/10.1038/modpathol.2013.214.Full Text
-
Ok, Chi Young, Zijun Y. Xu-Monette, Alexandar Tzankov, Dennis P. O’Malley, Santiago Montes-Moreno, Carlo Visco, Michael B. Møller, et al. “Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Cancer 120, no. 12 (June 2014): 1818–29. https://doi.org/10.1002/cncr.28664.Full Text
-
Ok, Chi Young, Ling Li, Zijun Y. Xu-Monette, Carlo Visco, Alexander Tzankov, Ganiraju C. Manyam, Santiago Montes-Moreno, et al. “Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 20, no. 9 (May 2014): 2338–49. https://doi.org/10.1158/1078-0432.ccr-13-3157.Full Text
-
Miranda, Roberto N., Tariq N. Aladily, H Miles Prince, Rashmi Kanagal-Shamanna, Daphne de Jong, Luis E. Fayad, Mitual B. Amin, et al. “Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 2 (January 2014): 114–20. https://doi.org/10.1200/jco.2013.52.7911.Full Text
-
Visco, C., Y. Li, Z. Y. Xu-Monette, R. N. Miranda, T. M. Green, A. Tzankov, W. Wen, et al. “Erratum: Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the international DLBCL rituximab-CHOP consortium program study (Leukemia (2014) 28 (980) Doi:10.1038/leu.2014.24).” Leukemia 28, no. 4 (January 1, 2014): 980. https://doi.org/10.1038/leu.2014.24.Full Text
-
Wang, Shi, Alexander Tzankov, Zijun Y. Xu-Monette, Sylvia Hoeller, Sa A. Wang, Kristy L. Richards, Shanxiang Zhang, Jonathan W. Said, L Jeffrey Medeiros, and Ken H. Young. “Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.” Hum Pathol 44, no. 12 (December 2013): 2658–67. https://doi.org/10.1016/j.humpath.2013.07.007.Full Text Link to Item
-
Frei, E., C. Visco, Z. Y. Xu-Monette, S. Dirnhofer, K. Dybkær, A. Orazi, G. Bhagat, et al. “Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.” Journal of Clinical Pathology 66, no. 11 (November 2013): 956–61. https://doi.org/10.1136/jclinpath-2013-201619.Full Text
-
Chou, Feng-Pai, Ya-Wen Chen, Xianfeng F. Zhao, Zijun Y. Xu-Monette, Ken H. Young, Ronald B. Gartenhaus, Jehng-Kang Wang, et al. “Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.” The American Journal of Pathology 183, no. 4 (October 2013): 1306–17. https://doi.org/10.1016/j.ajpath.2013.06.024.Full Text
-
Xu-Monette, Zijun Y., Michael B. Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu, Ganiraju C. Manyam, Louise Kristensen, et al. “MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Blood 122, no. 15 (October 2013): 2630–40. https://doi.org/10.1182/blood-2012-12-473702.Full Text Open Access Copy
-
Hu, Shimin, Zijun Y. Xu-Monette, Alexander Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, et al. “MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.” Blood 121, no. 20 (May 2013): 4021–4250. https://doi.org/10.1182/blood-2012-10-460063.Full Text Open Access Copy
-
Li, Yong, Michael W. Gordon, Zijun Y. Xu-Monette, Carlo Visco, Alexander Tzankov, Dehui Zou, Lugui Qiu, et al. “Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Blood 121, no. 22 (May 2013): 4529–40. https://doi.org/10.1182/blood-2012-12-471722.Full Text
-
Hu, Shimin, Zijun Y. Xu-Monette, Aarthi Balasubramanyam, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Wei-min Liu, et al. “CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Blood 121, no. 14 (April 2013): 2715–24. https://doi.org/10.1182/blood-2012-10-461848.Full Text Open Access Copy
-
Visco, Carlo, Alexander Tzankov, Zijun Y. Xu-Monette, Roberto N. Miranda, Yu Chuan Tai, Yan Li, Wei-min Liu, et al. “Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.” Haematologica 98, no. 2 (February 2013): 255–63. https://doi.org/10.3324/haematol.2012.066209.Full Text Link to Item
-
Hoeller, Sylvia, Yi Zhou, Rashmi Kanagal-Shamanna, Zijun Y. Xu-Monette, Daniela Hoehn, Michel Bihl, Steven H. Swerdlow, et al. “Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.” Human Pathology 44, no. 1 (January 2013): 110–21. https://doi.org/10.1016/j.humpath.2012.04.022.Full Text
-
Xu-Monette, Zijun Y., Lin Wu, Carlo Visco, Yu Chuan Tai, Alexander Tzankov, Wei-min Liu, Santiago Montes-Moreno, et al. “Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.” Blood 120, no. 19 (November 2012): 3986–96. https://doi.org/10.1182/blood-2012-05-433334.Full Text Open Access Copy
-
Green, Tina Marie, Ken H. Young, Carlo Visco, Zijun Y. Xu-Monette, Attilio Orazi, Ronald S. Go, Ole Nielsen, et al. “Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.” J Clin Oncol 30, no. 28 (October 1, 2012): 3460–67. https://doi.org/10.1200/JCO.2011.41.4342.Full Text Open Access Copy Link to Item
-
Visco, C., Y. Li, Z. Y. Xu-Monette, R. N. Miranda, T. M. Green, A. Tzankov, W. Wen, et al. “Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Leukemia 26, no. 9 (September 2012): 2103–13. https://doi.org/10.1038/leu.2012.83.Full Text Open Access Copy
-
Xu-Monette, Zijun Y., and Ken H. Young. “The TP53 tumor suppressor and autophagy in malignant lymphoma.” Autophagy 8, no. 5 (May 2012): 842–45. https://doi.org/10.4161/auto.19703.Full Text
-
Xu-Monette, Zijun Y., L Jeffrey Medeiros, Yong Li, Robert Z. Orlowski, Michael Andreeff, Carlos E. Bueso-Ramos, Timothy C. Greiner, Timothy J. McDonnell, and Ken H. Young. “Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.” Blood 119, no. 16 (April 19, 2012): 3668–83. https://doi.org/10.1182/blood-2011-11-366062.Full Text Link to Item
-
Green, Tina Marie, Ole Nielsen, Karin de Stricker, Zijun Y. Xu-Monette, Ken H. Young, and Michael Boe Møller. “High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.” The American Journal of Surgical Pathology 36, no. 4 (April 2012): 612–19. https://doi.org/10.1097/pas.0b013e318244e2ba.Full Text
-
Xu, Z., S. Rafi, and W. Ramakrishna. “Polymorphisms and evolutionary history of retrotransposon insertions in rice promoters.” Genome 54, no. 8 (August 2011): 629–38. https://doi.org/10.1139/g11-030.Full Text Link to Item
-
Montes-Moreno, Santiago, Nerea Martinez, Beatriz Sanchez-Espiridión, Ramon Díaz Uriarte, Maria Elena Rodriguez, Anabel Saez, Carlos Montalbán, et al. “miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.” Blood 118, no. 4 (July 28, 2011): 1034–40. https://doi.org/10.1182/blood-2010-11-321554.Full Text Link to Item
-
Rossi, Davide, Valeria Spina, Clara Deambrogi, Silvia Rasi, Luca Laurenti, Kostas Stamatopoulos, Luca Arcaini, et al. “The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.” Blood 117, no. 12 (March 2011): 3391–3401. https://doi.org/10.1182/blood-2010-09-302174.Full Text
-
Rasi, Silvia, Valeria Spina, Alessio Bruscaggin, Tiziana Vaisitti, Claudio Tripodo, Francesco Forconi, Lorenzo De Paoli, et al. “A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.” Br J Haematol 152, no. 3 (February 2011): 284–94. https://doi.org/10.1111/j.1365-2141.2010.08482.x.Full Text Link to Item
-
Visco, Carlo, Sylvia Hoeller, Jeffrey T. Malik, Zijun Y. Xu-Monette, Michele L. Wiggins, Jessica Liu, Warren G. Sanger, et al. “Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.” Am J Surg Pathol 35, no. 2 (February 2011): 177–89. https://doi.org/10.1097/PAS.0b013e3182049a9c.Full Text Open Access Copy Link to Item
-
Xu, Zijun, and Wusirika Ramakrishna. “Retrotransposon insertion polymorphisms in six rice genes and their evolutionary history.” Gene 412, no. 1–2 (April 15, 2008): 50–58. https://doi.org/10.1016/j.gene.2008.01.012.Full Text Link to Item
-
Nagy, Ervin D., Tso-Ching Lee, Wusirika Ramakrishna, Zijun Xu, Patricia E. Klein, Phillip SanMiguel, Chiu-Ping Cheng, et al. “Fine mapping of the Pc locus of Sorghum bicolor, a gene controlling the reaction to a fungal pathogen and its host-selective toxin.” Theor Appl Genet 114, no. 6 (April 2007): 961–70. https://doi.org/10.1007/s00122-006-0481-1.Full Text Link to Item
-
-
Conference Papers
-
Albitar, Maher, Zijun Yidan Xu-Monette, Babak Shahbaba, Ivan De Dios, Yingjun Wang, Deng Manman, Alexandar Tzankov, et al. “Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning.” In Blood, 134:2891–2891. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126927.Full Text
-
Albitar, Maher, Zijun Yidan Xu-Monette, Wanlong Ma, Yingjun Wang, Deng Manman, Alexandar Tzankov, Carlo Visco, et al. “Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma.” In Blood, 134:1499–1499. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-128516.Full Text
-
Wang, Yingjun, Ken H. Young, Denái R. Milton, Celina Ledesma, Elias Jabbour, Zijun Yidan Xu-Monette, Jeffrey J. Molldrem, et al. “Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation.” In Blood, 134:2021–2021. American Society of Hematology, 2019. https://doi.org/10.1182/blood-2019-126719.Full Text
-
Malaney, Prerna, Miguel Gallardo, Marisa J. Hornbaker, Xiaorui Zhang, Todd Link, Vrutant Shah, Sanzhar Alybayev, et al. “hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis.” In Blood, 132:1346–1346. American Society of Hematology, 2018. https://doi.org/10.1182/blood-2018-99-116163.Full Text
-
Rassidakis, George, Yi Miao, Jun Zhang, Vassilis Atsaves, Lorand Kis, Karin E. Smedby, Yong Li, Zijun Yidan Xu-Monette, and Ken H. Young. “PD-L1 Expression and Gene Amplification in CD30+Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.Link to Item
-
Xu-Monette, Zijun Yidan, Li Yu, Tran Thai, Lisa Adams, Nathan Roscoe, Ganiraju Manyam, Carlo Visco, et al. “Clinical Significance of PD-1 and PD-L1 Expression and Ongoing Interaction in the Tumor Microenvironment in Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.Link to Item
-
Xu-Monette, Zijun Y., and Ken H. Young. “Abstract 666: CD37 tetraspanin as a novel biomarker for PD-1 blockade in diffuse large B-cell lymphoma.” In Cancer Research, 77:666–666. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.am2017-666.Full Text
-
Chung, Elaine Y., Maurilio Ponzoni, Zijun Yidan Xu-Monette, Valdemar Priebe, Luciano Cascione, Eugenio Gaudio, Emanuele Zucca, Davide Rossi, Ken H. Young, and Francesco Bertoni. “ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma.” In Blood, 128:1755–1755. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.1755.1755.Full Text
-
Reinholz, Monica Madden, Debrah Thompson, Ihab Botros, Paul Sportmann, Qian Liu, Pat Roche, Zijun Xu-Monette, Ken H. Young, and Bonnie LaFleur. “Next generation sequencing for DLBCL classification.” In Journal of Clinical Oncology, 34:11559–11559. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11559.Full Text
-
Xu-Monette, Zijun Yidan, Debrah Thompson, Bonnie LaFleur, Patrick Roche, Monica Reinholz, John Wineman, Ken H. Young, and Ihab Botros. “Diffuse Large B-Cell Lymphoma Cell of Origin Determination from Formalin-Fixed Paraffin-Embedded Tissues.” In Blood, 126:5052–5052. American Society of Hematology, 2015. https://doi.org/10.1182/blood.v126.23.5052.5052.Full Text
-
Cao, Xin, Robert Z. Orlowski, Muzaffar Qazilbash, Zhiyu Liu, Zijun Y. Xu-Monette, L Jeffrey Medeiros, and Ken H. Young. “Extramedullary involvement at diagnosis is a poor prognostic factor in patients with Waldenstrom macroglobulinemia: The MD Anderson Cancer Center experience.” In Clinical Lymphoma Myeloma and Leukemia, 15:S229–S229. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.110.Full Text
-
Kirsch, I., Z. Xu-Monette, T. Snyder, and K. Young. “DEFINING IMMUNOGLOBULIN SOMATIC HYPERMUTATION IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: POTENTIAL APPLICATION FOR PROGNOSIS AND RISK STRATIFICATION.” In Haematologica, 100:111–12. FERRATA STORTI FOUNDATION, 2015.Link to Item
-
Li, Ling, Zijun Y. Xu-Monette, Chi Y. Ok, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Santiago Montes-Moreno, et al. “Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium.” In Clinical Lymphoma Myeloma and Leukemia, 15:S224–S224. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.101.Full Text
-
Liu, Zhiyu, Zijun Y. Xu-Monette, Xin Cao, Carlo Visco, Alexander Tzankov, Santiago Montes-Moreno, Karen Dybkær, et al. “Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 15:S216–S216. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.087.Full Text
-
Shen, Qi, Zijun Y. Xu-Monette, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Xin Cao, Lijuan Deng, et al. “Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 15:S220–21. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.096.Full Text
-
Xu-Monette, Zijun Y., Ganiraju C. Manyam, Alexander Tzankov, Qipan Deng, Carlo Visco, Meifeng Tu, Ling Li, et al. “MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma.” In Clinical Lymphoma Myeloma and Leukemia, 15:S223–S223. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.100.Full Text
-
Ye, Qinng, Zijun Y. Xu-Monette, Shimin Hu, Alexander Tzankov, Nora Gisin, Carlo Visco, Santiago Montes-Moreno, et al. “Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 15:S228–S228. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.109.Full Text
-
Dybkaer, Karen, Martin Bogsted, Steffen Falgreen, Malene Krag Kjeldsen, Alexander Schmitz, Julie Stove Bodker, Anders Ellern Bilgrau, et al. “A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Khouri, Issa F., Rima M. Saliba, Zijun Y. Xu-Monette, Martin Korbling, Gabriela Rondon, Rosamar Valverde, Amin M. Alousi, et al. “Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL).” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Kirsch, Ilan, Zijun Yidan Xu-Monette, Thomas Snyder, and Ken H. Young. “Defining Immunoglobulin Somatic Hypermutation in De Novo Diffuse Large B-Cell Lymphoma Patients: Potential Application for Prognosis and Risk Stratification.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Li, Ling, Zijun Yidan Xu-Monette, Chi Young Ok, Alexander Tzanko, Carlo Visco, Nora Gisin, Santiago Montes-Moreno, et al. “NF-kappa B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Loghavi, Sanam, Zijun Yidan Xu-Monette, Luis Fayad, Larry W. Kwak, Bouthaina S. Dabaja, L Jeffrey Medeiros, and Ken H. Young. “Clinical and Biological Features of Primary Testicular B-Cell Lymphoma - a Single-Institution Study of 89 Cases.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Shen, Qi, Zijun Yidan Xu-Monette, Ganiraju Manyam, Carlo Visco, Alexander Tzankov, Xin Cao, Lijuan Deng, et al. “Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.Link to Item
-
Ok, Chi Young, Zijun Y. Xu-Monette, Carlo Visco, Alexandar Tzankov, Santiago Montes-Moreno, Karen Dybkær, April Chiu, et al. “Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 14:S144–45. Elsevier BV, 2014. https://doi.org/10.1016/j.clml.2014.06.082.Full Text
-
Xu-Monette, Zijun Y., Michael B. Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu, Ganiraju C. Manyam, Louise Kristensen, et al. “Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 14:S146–47. Elsevier BV, 2014. https://doi.org/10.1016/j.clml.2014.06.085.Full Text
-
Khouri, Issa F., Rima M. Saliba, Zijun Y. Xu-Monette, Gabriela Rondon, Rosamar Valverde, Martin Korbling, Alison M. Gulbis, et al. “Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT).” In Blood, 122:3350–3350. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.3350.3350.Full Text
-
Ok, Chi Young, Zijun Y. Xu-Monette, Alexander Tzankov, Carlo Visco, Santiago M. Montes, Karen Dybkaer, April Chiu, et al. “STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report Fro The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.Link to Item
-
Xu-Monette, Zijun Y., Alexander Tzankov, Yong Li, Carlo Visco, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, et al. “MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.Link to Item
-
Xu-Monette, Zijun Y., Bouthaina S. Dabaja, Alexander Tzankov, Carlo Visco, Roberto N. Miranda, Karen Dybkaer, April Chiu, et al. “Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, 122:213–213. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.213.213.Full Text
-
Xu-Monette, Zijun Y., Bouthaina S. Dabaja, Alexander Tzankov, Carlo Visco, Roberto N. Miranda, Karen Dybkaer, April Chiu, et al. “Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, 122:641–641. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.641.641.Full Text
-
Zhou, Y., R. Kanagal-Shamanna, S. Hoeller, A. Tzankov, D. Hoehn, S. H. Swerdlow, A. Rosenwald, et al. “Molecular Characteristics of Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” In Laboratory Investigation, 92:385A-385A. NATURE PUBLISHING GROUP, 2012.Link to Item
-
Zhou, Y., R. Kanagal-Shamanna, S. Hoeller, A. Tzankov, D. Hoehn, S. H. Swerdlow, A. Rosenwald, et al. “Molecular Characteristics of Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” In Modern Pathology, 25:385A-385A. NATURE PUBLISHING GROUP, 2012.Link to Item
-
López, Ana Batlle, Sonia Glez de Villambrosia, Santiago Montes-Moreno, Francisco Mazorra, Andrés Insunza, Anabel Sáez, Carlos Montalban, et al. “Prognostic Value of cMYC Gene Abnormalities in Diffuse Large B Cell Lymphoma Treated with Chemo-Immunotherapy.” In Blood, 118:2664–2664. American Society of Hematology, 2011. https://doi.org/10.1182/blood.v118.21.2664.2664.Full Text
-
Visco, Carlo, Alexander Tzankov, Zijun Y. Xu-Monette, Roberto N. Miranda, Emanuele S. G. d’Amore, Santiago Montes-Moreno, Karen Dybkaer, et al. “The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study.” In Blood, 118:433–34. AMER SOC HEMATOLOGY, 2011.Link to Item
-
Rossi, Davide, Valeria Spina, Clara Deambrogi, Silvia Rasi, Luca Laurenti, Kostas Stamatopoulos, Luca Arcaini, et al. “The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship.” In Blood, 116:1482–1482. AMER SOC HEMATOLOGY, 2010.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.